Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme (Q40495113)

21 September 2017

Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme (English)

1 reference

21 September 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

1 reference

11

Eithan Galun

0 references

author name string

Arnold I Freeman

1

1 reference

21 September 2017

Zichria Zakay-Rones

2

1 reference

21 September 2017

John M Gomori

3

1 reference

21 September 2017

Eduard Linetsky

4

1 reference

21 September 2017

Linda Rasooly

5

1 reference

21 September 2017

Evgeniya Greenbaum

6

1 reference

21 September 2017

Shira Rozenman-Yair

7

1 reference

21 September 2017

Amos Panet

8

1 reference

21 September 2017

Eugene Libson

9

1 reference

21 September 2017

Charles S Irving

10

1 reference

21 September 2017

Tali Siegal

12

1 reference

21 September 2017

28 October 2005

1 reference

21 September 2017

1 reference

21 September 2017

13

1 reference

21 September 2017

1

1 reference

21 September 2017

221-228

1 reference

Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Targeted molecular therapy of GBM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Development of novel targeted therapies in the treatment of malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Oncolytic viruses for the therapy of brain tumors and other solid malignancies a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Reovirus as an oncolytic agent against experimental human malignant gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Newcastle disease virus (NDV): brief history of its oncolytic strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Newcastle disease virus selectively kills human tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

MTH-68/H oncolytic viral treatment in human high-grade gliomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

RIGging an antiviral defense--it's in the CARDs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Natural interferon alpha/beta-producing cells link innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Stimulation of human natural interferon-alpha response via paramyxovirus hemagglutinin lectin-cell interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Accelerated titration designs for phase I clinical trials in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

Response criteria for phase II studies of supratentorial malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.016

10.1016/J.YMTHE.2005.08.016

7 January 2021

Identifiers

DOI

1 reference

21 September 2017

1 reference